Introduction {#cen13045-sec-0007}
============

Each year, 1·4 million people attend emergency departments in England and Wales with a recent traumatic brain injury (TBI).[1](#cen13045-bib-0001){ref-type="ref"} TBI is a major cause of long‐term disability often leading to neuropsychiatric and cognitive impairments, including problems with memory and executive function, mood, sleep disturbance and lethargy. Recovery after TBI varies markedly between patients. Neuroendocrine dysfunction leading to pituitary hormone deficiencies after TBI may contribute to persistent symptoms, especially growth hormone deficiency, with 5--20% of TBI patients reported as having hypothalamic--pituitary dysfunction.[2](#cen13045-bib-0002){ref-type="ref"} Vitamin D is another hormonal factor that could influence recovery after TBI. Vitamin D is a fat‐soluble sercosteroid essential for musculoskeletal health that is primarily synthesized in the skin upon sun exposure. The prevalence of vitamin D deficiency may be increased after TBI because of reduced sun exposure as a result of hospitalization, impaired social functioning and absence from work, resulting in more time spent indoors.

Vitamin D deficiency has been associated with many systemic conditions, such as obesity, cardiovascular and neurodegenerative diseases.[3](#cen13045-bib-0003){ref-type="ref"}, [4](#cen13045-bib-0004){ref-type="ref"} Several meta‐analyses have linked vitamin D status to depression [5](#cen13045-bib-0005){ref-type="ref"}, [6](#cen13045-bib-0006){ref-type="ref"} (Table S2) and impaired cognitive function.[7](#cen13045-bib-0007){ref-type="ref"}, [8](#cen13045-bib-0008){ref-type="ref"}, [9](#cen13045-bib-0009){ref-type="ref"}, [10](#cen13045-bib-0010){ref-type="ref"} However, these clinical findings are from association studies and so it is difficult to infer causation as any disorder that decreases exposure to sunlight, such as depression, may cause vitamin D deficiency. Nevertheless, meta‐analyses of intervention studies have demonstrated improvements in depressive symptoms with vitamin D supplementation, especially if subjects are vitamin D deficient or clinically depressed at baseline (Table S3), which would motivate vitamin D replacement in clinical practice.

Depression and cognitive impairment are also common consequences after TBI, with the prevalence of depression ranging from 6 to 77%, and cognitive problems with memory, attention and executive functioning are frequently seen.[9](#cen13045-bib-0009){ref-type="ref"}, [10](#cen13045-bib-0010){ref-type="ref"} Vitamin D status may therefore play a role in the development or exacerbation of cognitive and psychiatric problems after TBI, impacting recovery and quality of life. Vitamin D receptors and the vitamin D‐activating enzyme, 1‐alpha‐hydroxylase, are widely distributed in the human brain.[11](#cen13045-bib-0011){ref-type="ref"} Importantly, animal studies show that vitamin D status can influence behavioural recovery, including memory, and neuropathology after TBI.[4](#cen13045-bib-0004){ref-type="ref"}, [12](#cen13045-bib-0012){ref-type="ref"} Neuroinflammation is a common consequence of TBI that may impair recovery,[13](#cen13045-bib-0013){ref-type="ref"} and may be a linking mechanism for the beneficial effects of vitamin D in rat models of TBI.[4](#cen13045-bib-0004){ref-type="ref"}, [12](#cen13045-bib-0012){ref-type="ref"}, [14](#cen13045-bib-0014){ref-type="ref"}

Vitamin D status is best assessed using serum 25‐hydroxy‐cholecalciferol, 25(OH)D3, concentration, as this is the major circulating form of vitamin D with a long half‐life of 2--3 weeks.[15](#cen13045-bib-0015){ref-type="ref"} United Kingdom national surveys suggest that approximately 20% of adults can have low vitamin D status,[16](#cen13045-bib-0016){ref-type="ref"} with seasonal variation meaning that in winter this can reach 50% of White adults.[17](#cen13045-bib-0017){ref-type="ref"} Levels are also lower in subjects with darker skin as melanin absorbs UV‐B radiation from sunlight.[18](#cen13045-bib-0018){ref-type="ref"} Vitamin D status can be classified as replete, insufficient or deficient, using established criteria (Table S1).

However, there are no published clinical data on the prevalence of vitamin D deficiency in patients after TBI or its association with poorer clinical outcomes. Therefore, the purpose of this retrospective cohort study was to determine the prevalence of vitamin D deficiency and insufficiency after TBI, and whether it is associated with severity of TBI, greater cognitive impairment, worse symptoms and quality of life.

Methods {#cen13045-sec-0008}
=======

Study design {#cen13045-sec-0009}
------------

Case records were retrospectively reviewed from 581 new patients attending the multidisciplinary adult TBI clinic at Charing Cross/St Mary\'s Hospitals, Imperial College Healthcare NHS Trust (ICHNT), London, UK, between July 2009 and March 2015, to collate data from their first outpatient appointment when vitamin D status was assessed. All data were collected as part of routine clinical care. Patients taking part in neuroimaging research also gave written consent to allow records to be accessed (Research Ethics Committee West London 09/H0707/82).

Inclusion/exclusion criteria {#cen13045-sec-0010}
----------------------------

Inclusion criteria were as follows: (i) either gender, (ii) any age, (iii) experienced at least one TBI of any severity[19](#cen13045-bib-0019){ref-type="ref"} and (iv) any ethnicity. Exclusion criteria were as follows: (i) no serum vitamin D concentration available; (ii) disorder affecting vitamin D, PTH or calcium physiology including inflammatory bowel disease, severe liver failure, small bowel injury, giardia, chronic diarrhoea, bariatric surgery, gastrostomy feeding, chronic renal failure, primary hyperparathyroidism, on phenytoin; (iii) pre‐TBI disorder affecting quality of life and mood, including psychiatric conditions (attention‐deficit hyperactivity disorder, anxiety, depression, schizophrenia, psychosis, learning difficulty), (iv) diabetes mellitus, current alcohol excess or drug abuse; (v) on vitamin D supplements; (vi) time since TBI \>60 months to avoid referral biases leading to worse recovery; and (vii) no ethnicity data.

Data collection {#cen13045-sec-0011}
---------------

The following data were collected: (i) patient demographics: age, gender, ethnicity, body mass index (BMI), time since TBI, time of year; (ii) measures of TBI severity: symptomatic, mild, moderate--severe from Mayo classification,[19](#cen13045-bib-0019){ref-type="ref"} duration of post‐traumatic amnesia (PTA), neurosurgery, epilepsy; (iii) cognitive function measured by Addenbrooke\'s Cognitive Examination‐Revised (ACE‐R)[20](#cen13045-bib-0020){ref-type="ref"}; (iv) symptom questionnaire scores: Beck Depression Inventory‐II (BDI‐II),[21](#cen13045-bib-0021){ref-type="ref"} Epworth daytime sleepiness score,[22](#cen13045-bib-0022){ref-type="ref"} Pittsburgh Sleep Quality Index (PSQI)[23](#cen13045-bib-0023){ref-type="ref"}; (v) quality‐of‐life questionnaire scores: Nottingham Health Profile (NHP),[24](#cen13045-bib-0024){ref-type="ref"} Short Form‐36 (SF‐36)[25](#cen13045-bib-0025){ref-type="ref"}; and (vi) medical and medication history.

Outcome measures taken \>1 month apart from vitamin D measurement were excluded from the analysis due to the potential for recovery over time (\>2 months for BMI given its greater stability). BMI measurements from patients with limb amputations were excluded as an inaccurate measure of body composition. As ACE‐R score in part depends on understanding, language and fluency, scores taken from individuals with clear English language difficulties reported in clinic were also excluded (*n* = 12 total, *n* = 6 darker skinned).

Serum vitamin D and parathyroid hormone {#cen13045-sec-0012}
---------------------------------------

Serum 25(OH)D3 and PTH concentrations were measured by the Department of Chemical Pathology, ICHNT, using Architect chemiluminescent microparticle immunoassay (CMIA) 25(OH)D3 assay and *in vitro* CMIA Architect Intact PTH assay (Abbott Laboratories, Wiesbaden, Germany). To convert vitamin D concentrations from nmol/L to ng/mL divide by 2·496. Vitamin D status was stratified into categories based on the ICHNT guidelines: normal \>70 nmol/l (\>28·0 ng/ml), insufficient 40--70 nmol/l (16·0--28·0 ng/ml) and deficient \<40 nmol/l (\<16·0 ng/ml). PTH was stratified into two categories based on standard laboratory ranges: normal 1·1--6·8 pmol/l; high \>6·8 pmol/l.

Covariates {#cen13045-sec-0013}
----------

Skin colour was characterized by ethnicity, as either lighter skinned (including White, European Caucasian, Middle Eastern, Chinese or South East Asian) or darker skinned (Black, Indian subcontinent, South Asian, or Mixed including these ethnicities). Season was determined using the date of vitamin D sampling. Winter referred to samples taken during Daylight Saving Time (DST) (1st November to 31st March), and summer to British Summer Time (BST) (1st April to 31st October).

Statistical analysis {#cen13045-sec-0014}
--------------------

Data were analysed using SPSS v.22 (IBM, Armonk, NY, USA). Each variable was tested for normality using the Kolmogorov--Smirnov test. Data are presented as median (interquartile range) (min--max) as they were non‐normally distributed. Nonparametric Kruskal--Wallis one‐way [anova]{.smallcaps} was used to determine differences between the three vitamin D status groups for continuous variables, and Mann--Whitney *U*‐test for the two PTH category groups. Chi‐squared tests were performed to determine differences between groups in categorical demographic variables.

Two‐way [anova]{.smallcaps} with *post hoc* least significance difference (LSD) test determined the influence of skin colour and season between‐subject variables on serum vitamin D concentrations. One‐way [ancova]{.smallcaps} with *post hoc* LSD test determined differences between vitamin D groups when controlling for covariates: age, gender, time since TBI and severity of TBI (classified as symptomatic mild or moderate--severe, or as PTA less or greater than 1 week). Log~10~‐transformed values were used for age and time since TBI, as they were not normally distributed.

Spearman\'s bivariate correlation coefficient examined the relationship between vitamin D concentrations and outcome measures. Partial correlation coefficients were determined when including covariates: age, gender, time since TBI and severity of TBI, in the model.

Significance was taken as *P* \< 0·05. Due to multiple comparisons between the subdomains of quality‐of‐life questionnaires, Bonferroni correction was applied to SF‐36 and NHP scores, with significance taken as *P* \< 0·006 in SF‐36 (9 subdomains) and *P* \< 0·008 in NHP (6 subdomains).

Results {#cen13045-sec-0015}
=======

Cohort demographics {#cen13045-sec-0016}
-------------------

After exclusion criteria were applied, 353 patients were included in the final analysis (Fig. [1](#cen13045-fig-0001){ref-type="fig"}). Only 3% of patients were excluded as they were on vitamin D supplementation. Demographic characteristics of the cohort are shown in Table [1](#cen13045-tbl-0001){ref-type="table-wrap"} and Table S4. As typical for TBI, patients were generally young men (median age 35·1 years, 74·8% male). 75·4% were of the lighter skinned ethnic categories. The causes of TBI were as follows: road traffic accidents (33%), falls (31%), assault (17%), sports injuries (6%), improvised explosive device blast TBI (5%), object falling on head (5%), other (1%) and unknown (2%).

![Patient inclusion and exclusion flow chart. Data on prevalence of vitamin D status are given at bottom of chart. Abbreviations: ADHD, attention‐deficit hyperactivity disorder; DM, diabetes mellitus; IBD, inflammatory bowel disease; PEG, percutaneous endoscopic gastrostomy; TBI, traumatic brain injury.](CEN-85-636-g001){#cen13045-fig-0001}

###### 

Demographic characteristics of cohort

  Variable         Units       *n*   All subjects                       *n*   Vitamin D replete                   *n*   Vitamin D insufficient                                                        *n*   Vitamin D deficient                                                                                                                                                     H or χ statistic   *P*
  ---------------- ----------- ----- ---------------------------------- ----- ----------------------------------- ----- ----------------------------------------------------------------------------- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ -------------------------------------------------------
  Age              (years)     353   35·1 \[26·6,48·3\] (16·6--88·1)    70    37·9 \[26·8,53·4\] (17·9--86·7)     119   36·4 \[28·3,50·2\] (19·9--87·1)                                               164   32·8 \[24·6,46·6\][\*](#cen13045-note-0002){ref-type="fn"} (16·6--88·1)                                                                                                 6·1                **0·047**
  Male             *n* (%)     353   264 (74·8%)                        70    47 (67·1%)                          119   86 (72·3%)                                                                    164   131 (79·9%)                                                                                                                                                             4·8                0·090[^†^](#cen13045-note-0002){ref-type="fn"}
  Darker‐skinned   *n* (%)     353   87 (24·6%)                         70    3 (4·3%)                            119   14 (11·8%)                                                                    164   70 (42·7%)[\*](#cen13045-note-0002){ref-type="fn"}, [^\#^](#cen13045-note-0002){ref-type="fn"}                                                                          55·0               **\<0·001** [^†^](#cen13045-note-0004){ref-type="fn"}
  BMI              (kg/m^2^)   325   25·0 \[22·4,27·8\] (14·8--44·0)    67    24·3 \[21·6,27·3\] (14·8--44·0)     113   26·2 \[23·5,29·1\][\*\*](#cen13045-note-0002){ref-type="fn"} (14·8--44·0)     145   24·8 \[22·2,27·5\][^\#\#^](#cen13045-note-0002){ref-type="fn"} (15·6--37·2)                                                                                             10·4               **0·005**
  Time since TBI   (months)    353   4·4 \[2·6,9·8\] (0·3--56·5)        70    4·4 \[2·8,10·8\] (1·0--35·4)        119   5·0 \[2·8,10·4\] (0·7--53·0)                                                  164   3·5 \[2·3,9·6) (0·3--56·5)                                                                                                                                              5·2                0·075
  Winter           *n* (%)     353   161 (45·6%)                        70    16 (22·9%)                          119   46 (38·7%)[\*](#cen13045-note-0002){ref-type="fn"}                            164   99 (60·4%)[\*](#cen13045-note-0002){ref-type="fn"}, [^\#^](#cen13045-note-0002){ref-type="fn"}                                                                          31·3               **\<0·001** [^†^](#cen13045-note-0004){ref-type="fn"}
  Vitamin D        (nmol/l)    353   42·0 \[28,6,63·9\] (10·0--163·0)   70    82·5 \[75·0, 96.7\] (70·0--163·0)   119   51·7 \[46·0,59·8\][\*\*\*](#cen13045-note-0002){ref-type="fn"} (40·0--69·2)   164   27·7 \[21·1,34·3\][\*\*\*](#cen13045-note-0002){ref-type="fn"}, [^\#\#^](#cen13045-note-0002){ref-type="fn"}, [^\#^](#cen13045-note-0002){ref-type="fn"} (10·0--39·9)   300·5              **\<0·001**
  PTH              (pmol/l)    337   5·0 \[3·4,6·5\] (1·3--17·7)        70    4·2 (3·0,5·3\] (1·8--12·4)          113   4·5 (3·2,6·2)[\*\*](#cen13045-note-0002){ref-type="fn"} (1·4--14·0)           154   5·4 \[4·3,7·2\][\*\*\*](#cen13045-note-0002){ref-type="fn"} (1·3--17·7)                                                                                                 21·1               **\<0·001**
  High PTH         (pmol/l)    337   72 (20·4%)                         70    8 (11·4%)                           113   20 (16·8%)                                                                    154   44 (26·8%)[\*](#cen13045-note-0002){ref-type="fn"}, [^\#^](#cen13045-note-0002){ref-type="fn"}                                                                          9·8                **0·008** [^†^](#cen13045-note-0002){ref-type="fn"}

Values stated as median \[interquartile range\] (min‐max) or *n* (%) for categorical variables.

Statistical results from Kruskal‐Wallis one‐way [anova]{.smallcaps} test, except for ^†^Chi‐squared test where *post‐hoc* results only displayed as *P* \< 0·05. Post‐hoc comparison between groups: \**P* \< 0·05, \*\**P* \< 0·01, \*\*\**P* \< 0·001 *vs* vitamin D replete; ^\#^ *P* \< 0·05, ^\#\#^ *P* \< 0·01, ^\#\#\#^ *P* \< 0·001 *vs* vitamin D insufficient. . *P* values in bold text indicate statistically significant results for ANOVA. Abbreviations: BMI, body mass index; PTH, parathyroid hormone; TBI, traumatic brain injury. To convert vitamin D concentrations from nmol/l to ng/ml divide by 2·496.

John Wiley & Sons, Ltd

Vitamin D status {#cen13045-sec-0017}
----------------

In total, 46·5% of patients had vitamin D deficiency and an additional 33·7% were insufficient, with only 19·8% being replete (Fig. [1](#cen13045-fig-0001){ref-type="fig"}). The expected relationship between low vitamin D and high PTH concentrations was seen (Table [1](#cen13045-tbl-0001){ref-type="table-wrap"}, Figure S1). There was a significant difference in age, skin colour, BMI, and season between the three vitamin D categories, but no differences were found in gender or time since TBI (Table [1](#cen13045-tbl-0001){ref-type="table-wrap"}). Patients with vitamin D deficiency were significantly younger than those who were replete (*P* \< 0·05). There were a greater proportion of darker skinned ethnicities present in the vitamin D‐deficient group compared with the other two groups (*P* \< 0·05). Patients with vitamin D insufficiency also had a higher BMI compared with patients in the other two groups. A significantly higher proportion of samples were taken in the winter in patients with vitamin D deficiency.

Season and skin colour {#cen13045-sec-0018}
----------------------

Vitamin D concentrations were affected by both season and skin colour (Fig. [2](#cen13045-fig-0002){ref-type="fig"}a). Darker skin ethnicities had significantly lower vitamin D compared with lighter skin ethnicities (effect size mean ± SEM (95% CI) 21·8 ± 2·8 nmol/l (16·3, 27·3), *F*(1,349) = 60·4, *P* \< 0·001, Cohen\'s d = 0·83). Vitamin D concentrations were significantly lower in the winter compared with the summer (effect size 13·2 ± 2·8 (7·7, 18·7), *F*(1,349) = 22·2, *P* \< 0·001, Cohen\'s d = 0·34). There was, however, no interaction between skin colour and season on vitamin D (*F*(1,349) = 1·970, *P* = 0·16).

![Relationship between Vitamin D status and skin colour, season, cognition and depressive symptoms. (a) Influence of skin colour and season on serum vitamin D concentrations; (b, c) influence of vitamin D status on (b) cognition assessed by ACE‐R scores and (c) depressive symptoms assessed by BDI‐II; and (d) correlation between serum vitamin D concentrations and ACE‐R score. Statistical results from (a) two‐way [anova]{.smallcaps} including skin colour and ethnicity as between‐subject factors, indicating a significant effect of skin colour and season but no interaction effect (*n* = 353); (b, c) one‐way [ancova]{.smallcaps} including vitamin D status group as between‐subject factor, correcting for age, gender, time since TBI and PTA duration \>1 week, \**P* \< 0·05, \*\**P* \< 0·01 (b: *n* = 27 replete, *n* = 66 insufficient, *n* = 77 deficient; c: *n* = 53 replete, *n* = 95 insufficient, *n* = 123 deficient); (d) *r* ~s~ indicates Spearman\'s correlation coefficient, *n* = 175. Abbreviations: ACE‐R, Addenbrooke\'s Cognitive Examination‐Revised, BDI‐II, Beck Depression Inventory‐II;PTA, post‐traumatic amnesia; TBI, traumatic brain injury. To convert vitamin D concentrations from nmol/l to ng/ml divide by 2·496.](CEN-85-636-g002){#cen13045-fig-0002}

Comparison with general population {#cen13045-sec-0019}
----------------------------------

To gain an estimation of whether the prevalence of vitamin D insufficiency/deficiency after TBI was greater than would be expected in the general population, our results were compared with a UK nationwide cohort study of White British subjects aged 45 years (Table [2](#cen13045-tbl-0002){ref-type="table-wrap"}).[17](#cen13045-bib-0017){ref-type="ref"} The prevalence of vitamin D concentrations \<40 and \<75 nmol/l in White British and European Caucasian patients after TBI was significantly higher than in the general population in summer (22 *vs* 15%, *P* = 0·037; 70 *vs* 61%, *P* = 0·022), but not in winter.

###### 

Prevalence of vitamin D deficiency in white Caucasians compared to a UK survey

                  *n*       Vitamin D                         
  --------------- --------- ---------------- ---------------- -----------------
  DST/Winter                                                  
  Current Audit   **119**   **21 (17·6%)**   **63 (52·9%)**   **108 (90·8%)**
  UK Survey       2850      441 (15·5%)      1328 (46·6%)     2482 (87·1%)
  Chi Statistic             0·41             1·85             2·76
  *P* Value                 0·52             0·17             0·097
  BST/Summer                                                  
  Current Audit   **142**   **5 (3·5%)**     **31 (21·8%)**   **100 (70·4%)**
  UK Survey       4587      147 (3·2%)       706 (15·4%)      2793 (60·9%)
  Chi Statistic             0·044            4·34             5·27
  *P* Value                 0·83             **0·037**        **0·022**

Prevalence of vitamin D status in current audit (for white Caucasians only) was compared using chi‐squared test to UK survey data for white Caucasians reported by Hypponen E and Power C. Hypovitaminosis D in British adults at age 45 year: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007 85:860--868.

Abbreviations: BST, British Summer Time; DST, Daylight Saving Time; UK, United Kingdom.

To convert vitamin D concentrations from nmol/l to ng/ml divide by 2·496. *P* values in bold text indicate statistically significant results.

John Wiley & Sons, Ltd

Markers of TBI severity {#cen13045-sec-0020}
-----------------------

There was no significant difference in markers of TBI severity: PTA duration, or prevalence of moderate--severe TBI, craniotomy or epilepsy between the vitamin D groups (Table [3](#cen13045-tbl-0003){ref-type="table-wrap"}). This remained nonsignificant even after correction for age, skin colour and season.

###### 

Relationship between vitamin D status and markers of TBI severity

  Variable              Units     *n*   All subjects   *n*   Vitamin Dreplete   *n*   Vitamin D insufficient   *n*   Vitamin D deficient   Uncorrected   Corrected for: age, skin color season                   
  --------------------- --------- ----- -------------- ----- ------------------ ----- ------------------------ ----- --------------------- ------------- --------------------------------------- --------------- ------
  Moderate‐Severe TBI   *n* (%)   353   263 (74·5%)    70    51 (72·9%)         119   93 (78·2%)               164   119 (72·6%)           1·26          0·53                                    0·99 F(2,347)   0·59
  PTA \> 1 day          *n* (%)   328   154 (43·3%)    66    33 (47·1%)         109   55 (46·2%)               153   66 (40·2%)            1·68          0·43                                    1·06 F(2,321)   0·35
  PTA \> 1 week         *n* (%)   328   67 (19·0%)     66    13 (18·6%)         109   27 (22·7%)               153   27 (16·5%)            2·01          0·37                                    1·13 F(2,321)   0·33
  Craniotomy            *n* (%)   353   2 (0·6%)       70    1 (1·4%)           119   1 (0·8%)                 164   0 (0%)                2·02          0·37                                    1·99 F(2,347)   0·14
  Epilepsy              *n* (%)   353   47 (13·3%)     70    10 (14·3%)         119   16 (13·4%)               164   21 (12·8%)            0·10          0·95                                    0·41 F(2,347)   0·67

Values stated as *n* (%).

Statistical results from Chi‐squared test, except for \*one way [ancova]{.smallcaps} when controlling for covariates. Abbreviations: PTA, post‐traumatic amnesia; TBI, traumatic brain injury.

John Wiley & Sons, Ltd

Vitamin D status and outcome measures {#cen13045-sec-0021}
-------------------------------------

Patients with Vitamin D deficiency had significantly lower ACE‐R scores compared to patients with vitamin D insufficiency (*P* = 0·003) (Table [4](#cen13045-tbl-0004){ref-type="table-wrap"}). This significance remained after correction for age, gender, time since TBI and TBI severity, using either PTA \>1 week (effect size 5·2 ± 1·6 (95% CI 2·1--8·3), *P* = 0·001, Cohen\'s d = 0·56) (Fig. [2](#cen13045-fig-0002){ref-type="fig"}b), or prevalence of moderate--severe TBI (effect size 4·9 ± 1·5 (1·9--7·9), *P* = 0·002, Cohen\'s d = 0·54), as markers of severity. After correction for these factors, patients with vitamin D deficiency also had significantly lower ACE‐R scores than patients who were replete (effect size 4·5 ± 2·1 (0·3--8·6), *P* = 0·034, Cohen\'s d = 0·48).

###### 

Relationship between vitamin D status and cognition, symptoms and quality of life

  Questionnaire                                          Max score   *n*   All Subjects             Vitamin D replete        Vitamin D insufficient   Vitamin D deficient                                                 Uncorrected   Corrected for: age, gender, moderate‐severe TBI, time since TBI   Corrected for: age, gender, PTA\>1 week, time since TBI                                     
  ------------------------------------------------------ ----------- ----- ------------------------ ------------------------ ------------------------ ------------------------------------------------------------------- ------------- ----------------------------------------------------------------- --------------------------------------------------------- ----------- ----- --------------- -----------
  ACE‐R                                                  100         175   91 \[82,95\] (53--100)   91 \[85,95\] (69--100)   93 \[87,96\] (53--100)   88 \[79,93\][^\#\#^](#cen13045-note-0013){ref-type="fn"}(60--100)   9·22          **0·010**                                                         3·03 *F*(2,168)                                           **0·005**   170   6·04 F(2,163)   **0·003**
  BDI‐II                                                 63          285   12 \[6,21\] (0--60)      13 \[4,24\] (0--37)      11 \[5,19\] (0--38)      12 \[6,24\] (0--60)                                                 3·05          0·22                                                              4·15 *F*(2,278)                                           **0·017**   271   4·82 F(2,264)   **0·009**
  Epworth                                                24          260   7 \[2,11\] (0--22)       6 \[2,10\] (0--17)       8 \[3,12\] 10--22)       7 \[3,11\] (0--20)                                                  2·42          0·30                                                              1·46 *F*(2,253)                                           0·23        247   0·97 F(2,240)   0·38
  PSQI                                                   21          134   7 \[5,11\] (0--19)       7 \[6,11\] (1--18)       6 \[4,10\] (1--19)       7 \[4,12\] (0--19)                                                  1·27          0·53                                                              0·59 *F*(2,127)                                           0·55        125   0·80 F(2,118)   0·45
  SF‐36 (QoL)[^†^](#cen13045-note-0013){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                
  Physical Functioning                                   100         177   70 \[48,91\] (0--100)    63 \[21,90\] (5--100)    75 \[55,95\] (20--100)   70 \[46,92\] (0--100)                                               3·93          0·14                                                              2·59 *F*(2,170)                                           0·078       166   3·16 F(2,159)   0·045
  Role‐Physical                                          100         168   0 \[0,75\] (0--100)      0 \[0,75\] (0--100)      0 \[0,94\] (0--100)      0 \[0,75\] (0--100)                                                 0·37          0·83                                                              0·18 *F*(2,161)                                           0·83        159   0·26 F(2,152)   0·77
  Role‐Emotional                                         100         167   33 \[0,100\] (0--100)    0 \[0,67\] (0--100)      33 \[0,100\] (0--100)    67 \[0,100\] (0--100)                                               5·05          0·080                                                             1·69 *F*(2,160)                                           0·19        158   1·74 F(2,151)   0·18
  Energy Fatigue                                         100         175   45 \[25,60\] (0--95)     43 \[25,60\] (5--90)     43 \[25,56\] (0--95)     45 \[28,60\] (0--95)                                                0·20          0·91                                                              0·02 *F*(2,168)                                           0·98        165   0·00 F(2,158)   0·99
  Emotional Wellbeing                                    100         176   60 \[48,80\] (0--100)    56 \[41,71\] (12--92)    62 \[48,80\] (0--96)     64 \[48,80\] (0--100)                                               2·52          0·28                                                              0·64 *F*(2,169)                                           0·53        166   0·33 F(2,159)   0·72
  Social Functioning                                     100         178   50 \[25,75\] (0--100)    50 \[25,75\] (13--100)   50 \[25,75\] (0--100)    50 \[25,75\] (0--100)                                               0·58          0·75                                                              0·25 *F*(2,171)                                           0·78        168   0·27 F(2,161)   0·76
  Pain                                                   100         178   58 \[33,80\] (0--100)    45 \[33,90\] (0--100)    58 \[39,90\] (0--100)    59 \[34,78\] (0--100)                                               0·43          0·81                                                              0·26 *F*(2,171)                                           0·78        168   0·34 F(2,161)   0·72
  General Health                                         100         179   55 \[40,75\] (0--100)    60 \[33,75\] (0--100)    53 \[40,71\] (5--100)    55 \[35,75\] (0--100)                                               0·30          0·86                                                              0·16 *F*(2,172)                                           0·86        168   0·30 F(2,151)   0·74
  Health Change                                          100         176   25 \[25,50\] (0--100)    25 \[0,50\] (0--100)     25 \[25,50\] (0--100)    25 \[25,50\] (0--100)                                               4·39          0·11                                                              2·38 *F*(2,169)                                           0·095       165   2·27 F(2,158)   0·11
  NHP (QoL)[^‡^](#cen13045-note-0014){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                  
  Energy Levels                                          100         172   39 \[0,100\] (0--100)    62 \[6,100\] (0--100)    37 \[0,63\] (0--100)     37 \[0,100\] (0--100)                                               1·95          0·38                                                              0·77 *F*(2,165)                                           0·47        161   1·44 F(2,154)   0·24
  Pain                                                   100         166   9 \[0,33\] (0--100)      13 \[0,38\] (0--100)     0 \[0,18\] (0--100)      8 \[0,36\] (0--100)                                                 1·37          0·51                                                              0·94 *F*(2,159)                                           0·40        156   1·87 F(2,149)   0·16
  Emotional Reaction                                     100         161   20 \[0,53\] (0--100)     30 \[10,63\] (0--90)     17 \[0,40\] (0--93)      23 \[0,62\] (0--100)                                                3·01          0·22                                                              1·68 *F*(2,154)                                           0·19        151   2·25 F(2,144)   0·11
  Sleep                                                  100         164   28 \[0,57\] (0--100)     34 \[10,52\] (0--100)    15 \[0,50\] (0--100)     79 \[0,61\] (0--100)                                                1·22          0·54                                                              0·59 *F*(2,157)                                           0·55        154   0·55 F(2,147)   0·58
  Social Isolation                                       100         164   0 \[0,54\] (0--100)      23 \[0,62\] (0--100)     0 \[0,37\] (0--100)      0 \[0,64\] (0--100)                                                 4·57          0·10                                                              2·06 *F*(2,157)                                           0·13        154   2.29 F(2,147)   0·11
  Physical Activity                                      100         163   9 \[0,31\] (0--100)      11 \[0,34\] (0--79)      0 \[0,21\] (0--67)       0 \[0,33\] (0--100)                                                 1·55          0·46                                                              1·24 *F*(2,156)                                           0·29        153   1·68 F(2,146)   0·19
  Average                                                100         152   22 \[7,43\] (0--98)      26 \[17,50\] (0--81)     19 \[6,34\] (0--72)      23 \[7,48\] (0--98)                                                 3·10          0·21                                                              1·93 *F*(2,145)                                           0·15        142   2·72 F(2,135)   0·069
  NHP‐II                                                 7           176   3 \[1,6\] (0--7)         4 \[2,6\] (0--7)         3 \[1,5\] (0--7)         3 \[1,6\] (0--7)                                                    2·63          0·27                                                              1·54 *F*(2,169)                                           0·22        166   2·09 F(2,159)   0·13

Values stated as median \[interquartile range\] (min‐max)

Statistical results from Kruskal‐Wallis one‐way [anova]{.smallcaps} test, except for \*one way [ancova]{.smallcaps} when controlling for covariates

^\#\#^ *P* \< 0·01 *vs* vitamin D insufficient. *P* values in bold text indicate statistically significant results for ANOVA.

Abbreviations: ACE‐R, Addenbrooke\'s Cognitive Examination Revised; BDI‐II, Beck Depression Inventory II; NHP, Nottingham Health Profile; PSQI, Pittsburgh

Sleep Quality Index; QoL, quality of life; SF‐36, Short Form 36 Health Survey.

^†^SF‐36: higher score = better performance.

^‡^NHP: lower score = better performance.

John Wiley & Sons, Ltd

In stepwise linear regression, vitamin D status (F‐to‐enter = 6·70, *r* = +0·18, *P* = 0·010), but not skin colour (*P* = 0·57) or season (*F* = 0·28), also correlated with ACE‐R score. Additionally, this significance also remained when the analysis was restricted to just lighter skin ethnic individuals, in order to exclude many of those who may be less proficient in English as a second language (*F*(2,124) = 4·5, *P* = 0·013; effect size *vs* insufficient, 5·4 ± 1·8 (1·8--9·1), *P* = 0·004, Cohen\'s d = 0·59; effect size *vs* replete, 4·6 ± 2·3 (0·01--9·11), *P* = 0·050, Cohen\'s d = 0·49).

In the uncorrected model, vitamin D status was not significantly associated with BDI‐II score (Table [4](#cen13045-tbl-0004){ref-type="table-wrap"}). However, patients with vitamin D deficiency had significantly higher BDI‐II scores compared to those with insufficiency when corrected for age, gender, time since TBI and TBI severity, using both PTA \>1 week (effect size 4·9 ± 1·6 (1·7--8·1), *P* = 0·003, Cohen\'s d = 0·42) (Fig. [2](#cen13045-fig-0002){ref-type="fig"}c) or prevalence of moderate--severe TBI (effect size 4·3 ± 1·5 (1·3--7·4), *P* = 0·005, Cohen\'s d = 0·38). Season had no significant effect on BDI‐II score (winter vs. summer effect size −1·5 ± 1·3 (−4·2, 1·1), *P* = 0·25, Cohen\'s d = 0·14).

Vitamin D status did not influence Epworth daytime sleepiness or PSQI scores, or any components of the SF‐36 and NHP questionnaires, even after correction for age, gender, time since TBI and TBI severity (Table [4](#cen13045-tbl-0004){ref-type="table-wrap"}).

Vitamin D concentrations and outcome measures {#cen13045-sec-0022}
---------------------------------------------

Vitamin D concentrations were significantly correlated with performance on the ACE‐R (*r* ~s~ = +0·18, *P* = 0·017) (Table S5). This remained significant when corrected for age, gender, time since TBI and TBI severity, using both PTA \>1 week (*r* ~s~ = +0·18, *P* = 0·021) (Fig. [2](#cen13045-fig-0002){ref-type="fig"}d) and prevalence of moderate--severe TBI (*r* ~s~ = +0·18, *P* = 0·017).

There was, however, no significant correlation between vitamin D concentrations and symptom scores on BDI‐II, Epworth or PSQI, or quality‐of‐life measures from SF‐36 or NHP (Table S5).

PTH status and outcome measures {#cen13045-sec-0023}
-------------------------------

There was no significant association between PTH status, defined as high or normal, and cognition, symptoms scores or quality‐of‐life measures in either the whole cohort (*P* = 0·21--0·94), or those that were vitamin D deficient (*P* = 0·14--0·99), insufficient (*P* = 0·07--0·96) or nonreplete (*P* = 0·10--0·93).

Discussion {#cen13045-sec-0024}
==========

This study has found that vitamin D deficiency is common in patients after TBI with 46·5% of patients being vitamin D deficient, and a further 33·7% being insufficient, with overall 80·2% having low concentrations. This prevalence of vitamin D insufficiency/deficiency in summer in White and European Caucasian individuals after TBI was greater than expected in the general population (using a UK nationwide cohort study of the White British population aged 45 years).[17](#cen13045-bib-0017){ref-type="ref"} This was despite the fact that the UK survey included areas of greater latitude, such as Scotland, with higher prevalence of vitamin D deficiency, which would be expected to attenuate this difference.

In agreement with other studies in non‐TBI patients,[7](#cen13045-bib-0007){ref-type="ref"}, [8](#cen13045-bib-0008){ref-type="ref"} this study found that low vitamin D status was negatively correlated with cognition as assessed by the ACE‐R, even after adjustment for factors that may influence performance, including age, gender, time since TBI and TBI severity.[26](#cen13045-bib-0026){ref-type="ref"}, [27](#cen13045-bib-0027){ref-type="ref"}, [28](#cen13045-bib-0028){ref-type="ref"}

When corrected for age, gender, and other factors that may influence BDI‐II score,[29](#cen13045-bib-0029){ref-type="ref"}, [30](#cen13045-bib-0030){ref-type="ref"} vitamin D deficiency was also associated with more severe depressive symptoms. This is in agreement with previous meta‐analyses in non‐TBI patients, which show an association between vitamin D concentrations and depression (Table S2).[5](#cen13045-bib-0005){ref-type="ref"}, [6](#cen13045-bib-0006){ref-type="ref"}

These associations with cognition and depressive symptoms may result from a role for vitamin D in brain function.[31](#cen13045-bib-0031){ref-type="ref"} Many brain cell types and regions can synthesize the active form of vitamin D, 1,25(OH)D3, including the hypothalamus and substantia nigra,[11](#cen13045-bib-0011){ref-type="ref"} areas implicated in the pathophysiology of depression. Vitamin D modulates the production of neuroprotective factors and neurotransmitters (including growth factors and choline acetyltransferase), neuronal apoptosis, neuroinflammation, oxidative stress, excitotoxicity, and myelin and axon repair.[8](#cen13045-bib-0008){ref-type="ref"}, [32](#cen13045-bib-0032){ref-type="ref"}

In rat models of TBI, vitamin D deficiency leads to greater open‐field behavioural deficits and attenuates the beneficial effects of progesterone administration.[4](#cen13045-bib-0004){ref-type="ref"} This is reversed by co‐administration of vitamin D,[4](#cen13045-bib-0004){ref-type="ref"} which also improves spatial memory processing.[12](#cen13045-bib-0012){ref-type="ref"} Changes in neuroinflammation may be a linking mechanism as vitamin D deficiency is associated with elevated brain inflammatory proteins with, and even without, TBI.[4](#cen13045-bib-0004){ref-type="ref"} Vitamin D administration reduces neuronal loss and modifies the proliferation of reactive astrocytes.[12](#cen13045-bib-0012){ref-type="ref"}, [14](#cen13045-bib-0014){ref-type="ref"}

There was no association found between vitamin D status and sleep, or any quality‐of‐life domains on the NHP and SF‐36. This is contradictory to previous research in premenopausal women, and women with chronic pain (unlike current study where 74·8% were male), where vitamin D deficiency is associated with worse SF‐36 and NHP quality‐of‐life scores, particularly in vitality, physical and mental component subscores.[33](#cen13045-bib-0033){ref-type="ref"}, [34](#cen13045-bib-0034){ref-type="ref"} However, there are many factors that may affect quality of life, in addition to mood and cognitive function.

It is hypothesized that TBI may increase the prevalence of vitamin D insufficiency/deficiency as a result of hospitalization, impaired social functioning and absence from work, reducing sun exposure. However, in this audit, no markers of TBI severity influenced vitamin D status. This may be related to type II errors as some of the measures, such as need for neurosurgery and presence of epilepsy, were uncommon. In addition, TBI severity determined by duration of PTA and presence of intracranial pathology may not be relevant as a risk factor for sun exposure, given that the median time after TBI was 4·4 months.

Furthermore, vitamin D plays a major role in bone homoeostasis and can reduce risk of fracture and rate of bone loss in those over 50 years old.[35](#cen13045-bib-0035){ref-type="ref"} Thus, irrespective of the relationship between vitamin D status and cognition/depression, screening and treating patients after TBI could be justified to improve healing of any associated fractures, and bone health, especially as they become less active. This is a neglected treatment avenue as only 3% of our cohort were taking vitamin D supplements when vitamin D status was initially assessed at their first TBI clinic appointment.

There are several limitations with this study. Most importantly, this is an association study, and so the direction of causality seen in the results is unknown. Although vitamin D deficiency may be contributing to impaired cognitive function or higher depressive symptoms, this cannot be proven from this study. TBI itself can cause these symptoms, leading to individuals spending more time indoors and thus becoming more vitamin D deficient. However, meta‐analyses of intervention studies in non‐TBI patients have shown that vitamin D supplementation improves depressive symptoms, suggesting causation (Table S3). There is a currently a lack of intervention studies looking at the effects of vitamin supplementation and cognition, and further work is needed to clarify the direction of this association. Furthermore, this audit did not include a control group to allow comparison of prevalence data in individuals utilizing the same vitamin D assay. Finding a suitable control group from other studies is difficult due to differences in demographics and variability in the assay used.

There are also limitations regarding categorizing skin colour based on ethnicities of patients. Although Middle Eastern and eastern European individuals were considered to be lighter skinned, they may have greater levels of melanin than White Caucasians. Similarly, the categorization of season into DST and BST does not allow separation of all four seasons. However, appropriate relationships were seen between skin colour and season with vitamin D in our study, indicating that our approach gave biologically relevant results.[17](#cen13045-bib-0017){ref-type="ref"}, [18](#cen13045-bib-0018){ref-type="ref"} Reduced strength and duration of sunlight during winter and diversity of ethnicity in the UK will increase the clinical risk of vitamin D deficiency in our TBI clinic population.

Due to the potential limitations with the ACE‐R in those less proficient in English, a further development would be to use only measures of cognitive function that do not depend on language, such as memory, visuospatial and attention/orientation subcomponents. Alternatively, neuropsychological tests more specific to consequences after TBI could be used, for example focusing on planning, concentration and switching.

In conclusion, vitamin D deficiency is common in patients after TBI and is associated with worse cognitive function and more severe depressive symptoms. There is a potential for vitamin D to be a modifiable risk factor to improve recovery after TBI. Further work is needed to examine the longitudinal effects of vitamin D status and supplementation on neurocognitive and psychological function and neuroimaging biomarkers to determine whether assessment and treatment of vitamin D deficiency should become part of clinical guidelines in the management of TBI.
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